Johnson & Johnson (J&J) has started a phase 3 trial for the JNJ-78436735 (Ad26.COV2.S) vaccine candidate developed by Janssen Pharmaceutical Companies for the prevention of Covid-19.
Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis.
Chinese biopharmaceutical company Sinovac Biotech has begun phase III clinical trials for its inactivated Covid-19 vaccine candidate in Turkey.
Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer.
Bristol Myers Squibb (BMS) said that the phase 3 CheckMate -649 trial showed that the Opdivo (nivolumab) plus chemotherapy delivered significant overall and progression-free survival benefits in first-line treatment of gastric and esophageal cancers.
Merck announced new and updated findings from the Phase 3 EORTC1325/KEYNOTE-054 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
Seattle Genetics and Astellas Pharma said that PADCEV (enfortumab vedotin-ejfv) met the primary endpoint of overall survival (OS) in a confirmatory phase 3 trial in previously treated locally advanced or metastatic urothelial cancer.
CuraSen Therapeutics announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.
Melior Pharmaceuticals has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to support rapid advancement of promising COVID-19 therapies.
Daiichi Sankyo Company announced that the first patient has been dosed in a phase 2 study evaluating patritumab deruxtecan (U3-1402), a HER3 directed DXd antibody drug conjugate (ADC), in patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least two prior lines of systemic therapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.